Diagnosis and Treatment of Myasthenia Gravis

Renato Mantegazza; Paola Cavalcante


Curr Opin Rheumatol. 2019;31(6):623-633. 

In This Article


In the last few years, we have observed the onset of new categories of drugs, that is the complement inhibitors and the neonatal FcR blockers, which will progressively bring us into the reality of a precision medicine in myasthenia gravis. Results from the recently concluded clinical trials of biologicals, including eculizumab and efgartigimod, are expected to produce a significant change in the paradigms of treatment, illustrated in Figure 3, with a strong impact on myasthenic patients' management. The identification of biomarkers able to predict the efficacy of these drugs in individual patients will lead to the development of personalized medicine, that could significantly increase therapeutic success and the cost/effectiveness ratio for the disease treatment.